ソナゾイド造影超音波によるArrival time parametric imagingを用いた進行肝細胞癌に対するソラフェニブの早期治療評価の検討

概要

論文の詳細を見る
To determine the usefulness of arrival time parametric imaging (AtPI) using contrast-enhanced ultrasonography (CEUS) with Sonazoid in evaluating early response to sorafenib for hepatocellular carcinoma (HCC). 27 advanced HCC patients who received sorafenib for at least 4 weeks were enrolled in this study. CEUS was performed before and 2 weeks after treatment, and the images of the target lesion in the arterial phase were analyzed by AtPI. In each patient, differences of mean time (MT) obtained by AtPI between before and 2 weeks after treatment were compared. MT(+) and MT(-) was defined that the difference was zero or greater and less than zero, respectively. The overall survival was evaluated between MT(+) and MT(-) group. MT(+) group was 19 and MT(-) group was 8 patients. In the MT(+) and MT(-) group, the median survival time were 436 and 174 days, respectively, which was statistically significant. AtPI is suggested to be useful for evaluating early responses to sorafenib.